Literature DB >> 14696105

Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers.

Elaine M Smith1, Justine M Ritchie, Kurt F Summersgill, Jens P Klussmann, John H Lee, Donghong Wang, Thomas H Haugen, Lubomir P Turek.   

Abstract

There are few well-established patient risk factors associated with human papillomavirus (HPV) infection in cancers of the oral cavity and oropharynx. The purpose of this study was to determine if there were significant different risk factors and tumor characteristics between HPV-positive and HPV-negative cancer cases. HPV was evaluated in cancer tissue and exfoliated oral cells of 193 oral cavity/oropharynx cancer patients using PCR and direct DNA sequencing. A patient questionnaire collected information about risk factors, sexual practices and medical history. The prevalence of HPV high-risk (HR) types was 20% in cancer cases. Three types were identified: HPV-16 (87%), HPV-18 (3%) and HPV-33 (11%). Risk factors for HPV-HR included younger age (< or = 55 years vs. > 55 years; adjusted OR = 3.4; 95% CI = 1.6-7.3) and younger-age cases who had more lifetime sex partners (adjusted OR = 3.8; 95% CI = 1.4-10.1), practiced oral-genital sex (adjusted OR = 4.3; 95% CI = 1.8-10.4) or oral-anal sex (adjusted OR = 19.5; 95% CI = 3.4-113). Compared to HPV-negative cancers, HPV-HR cancers were more likely to have a positive HPV-HR exfoliated oral cytology test (adjusted OR = 7.8; 95% CI = 3.4-18.4), later stage (adjusted OR = 3.0), nodal involvement (adjusted OR = 4.1) and advanced grade (adjusted OR = 3.0). This study shows new evidence that the prevalence of oncogenic mucosal HPV is higher in younger-age oral cavity/oropharynx cancer cases whose sexual practices are typically associated with sexual transmission of the virus. HPV detection also appears to be an indicator of advanced disease characteristics that may require different clinical treatment for this subset of patients. An exfoliated oral cytology test for HPV was a significant predictor of HR types in the cancers, suggesting that an oral rinse may provide an early biomarker of infected tumors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14696105     DOI: 10.1002/ijc.11633

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  142 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival.

Authors:  Evgenia Gubanova; Brandee Brown; Sergei V Ivanov; Thomas Helleday; Gordon B Mills; Wendell G Yarbrough; Natalia Issaeva
Journal:  Clin Cancer Res       Date:  2012-01-13       Impact factor: 12.531

Review 3.  The role of HPV in head and neck cancer and review of the HPV vaccine.

Authors:  Gypsyamber D'Souza; Amanda Dempsey
Journal:  Prev Med       Date:  2011-10       Impact factor: 4.018

Review 4.  [Update on HPV-induced oropharyngeal cancer].

Authors:  S F Preuss; J-P Klussmann; R Semrau; C Huebbers
Journal:  HNO       Date:  2011-10       Impact factor: 1.284

Review 5.  Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects.

Authors:  Jan Klozar; Ruth Tachezy; Eliška Rotnáglová; Eva Košlabová; Martina Saláková; Eva Hamšíková
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 6.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

7.  Trends in incidence of oral and pharyngeal carcinoma in Florida: 1981-2008.

Authors:  Susan P McGorray; Yi Guo; Henrietta Logan
Journal:  J Public Health Dent       Date:  2011-09-19       Impact factor: 1.821

8.  Sex disparities in cancer mortality and survival.

Authors:  Michael B Cook; Katherine A McGlynn; Susan S Devesa; Neal D Freedman; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

9.  Sex disparities in cancer incidence by period and age.

Authors:  Michael B Cook; Sanford M Dawsey; Neal D Freedman; Peter D Inskip; Sara M Wichner; Sabah M Quraishi; Susan S Devesa; Katherine A McGlynn
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

10.  Combined effects of smoking and HPV16 in oropharyngeal cancer.

Authors:  Devasena Anantharaman; David C Muller; Pagona Lagiou; Wolfgang Ahrens; Ivana Holcátová; Franco Merletti; Kristina Kjærheim; Jerry Polesel; Lorenzo Simonato; Cristina Canova; Xavier Castellsague; Tatiana V Macfarlane; Ariana Znaor; Peter Thomson; Max Robinson; David I Conway; Claire M Healy; Anne Tjønneland; Ulla Westin; Johanna Ekström; Jenny Chang-Claude; Rudolf Kaaks; Kim Overvad; Dagmar Drogan; Göran Hallmans; Göran Laurell; H B Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Nerea Larrañaga; Ruth C Travis; Domenico Palli; Aurelio Barricarte; Antonia Trichopoulou; Saitakis George; Dimitrios Trichopoulos; J Ramón Quirós; Sara Grioni; Carlotta Sacerdote; Carmen Navarro; María-José Sánchez; Rosario Tumino; Gianluca Severi; Marie-Christine Boutron-Ruault; Francoise Clavel-Chapelon; Salvatore Panico; Elisabete Weiderpass; Eiliv Lund; Inger T Gram; Elio Riboli; Michael Pawlita; Tim Waterboer; Aimée R Kreimer; Mattias Johansson; Paul Brennan
Journal:  Int J Epidemiol       Date:  2016-05-19       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.